Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Diffuse midline gliomas (DMGs) are aggressive pediatric brain cancers driven by Histone 3 gene mutations.
• These mutations cause widespread epigenetic dysregulation, including loss of H3K27me3 repressive marks.
• Current therapies for DMGs are ineffective, necessitating novel therapeutic strategies.

Purpose of the Study:

• To identify therapeutically targetable dependencies in DMG by screening epigenetic and chromatin-associated genes.
• To investigate the role of the super elongation complex (SEC) in DMG pathogenesis.
• To evaluate the efficacy of SEC inhibition as a potential therapeutic approach for DMGs.

Main Methods:

• Performed an RNAi screen targeting epigenetic/chromatin-associated genes in patient-derived DMG cultures.
• Interrogated the function of AFF4 and the SEC in maintaining tumor stem cell properties.
• Utilized clinically relevant CDK9 inhibitors to target SEC activity in vitro and in vivo.

Main Results:

• Identified AFF4, a scaffold protein of the SEC, as a molecular dependency in DMG.
• Demonstrated that SEC maintains clonogenic potential and self-renewal of DMG stem cells.
• Showed that SEC inhibition with CDK9 inhibitors restores RNA polymerase II pausing, promotes differentiation, and exerts potent anti-tumor effects in vitro and in xenograft models.

Conclusions:

• The super elongation complex (SEC) is a critical dependency in diffuse midline gliomas.
• Inhibition of SEC using CDK9 inhibitors represents a promising therapeutic strategy for pediatric brain cancers like DMGs.
• Targeting SEC offers a novel approach to overcome treatment resistance in intractable pediatric brain tumors.